Highly Effective, Regiospecific Hydrogenation of Methoxychalcone
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Metabolic Engineering of Saccharomyces Cerevisiae for De Novo Production of Dihydrochalcones with Known Antioxidant, Antidiabetic, and Sweet Tasting Properties
Metabolic Engineering xx (xxxx) xxxx–xxxx Contents lists available at ScienceDirect Metabolic Engineering journal homepage: www.elsevier.com/locate/ymben Original Research Article Metabolic engineering of Saccharomyces cerevisiae for de novo production of dihydrochalcones with known antioxidant, antidiabetic, and sweet tasting properties Michael Eichenbergera,b, Beata Joanna Lehkac,d, Christophe Follya, David Fischera, ⁎ Stefan Martense, Ernesto Simóna, Michael Naesbya, a Evolva SA, Duggingerstrasse 23, 4153 Reinach, Switzerland b Department of Biology, Technical University Darmstadt, Schnittspahnstrasse 10, 64287 Darmstadt, Germany c Evolva Biotech A/S, Lersø Parkallé 42, 2100 Copenhagen, Denmark d Department of Science and Environment, Roskilde University, Universitetsvej 1, 4000 Roskilde, Denmark e Department of Food Quality and Nutrition, Fondazione Edmund Mach, Centro Ricerca e Innovazione, Via E. Mach 1, 38010 San Michele all’Adige (TN), Italy ARTICLE INFO ABSTRACT Chemical compounds studied in this article: Dihydrochalcones are plant secondary metabolites comprising molecules of significant commercial interest as Phloretin (PubChem CID: 4788) antioxidants, antidiabetics, or sweeteners. To date, their heterologous biosynthesis in microorganisms has been Naringenin (PubChem CID: 932) achieved only by precursor feeding or as minor by-products in strains engineered for flavonoid production. Pinocembrin (PubChem CID: 68071) Here, the native ScTSC13 was overexpressed in Saccharomyces cerevisiae to increase its side activity in Phlorizin (PubChem CID: 6072) reducing p-coumaroyl-CoA to p-dihydrocoumaroyl-CoA. De novo production of phloretin, the first committed Nothofagin (PubChem CID: 42607691) dihydrochalcone, was achieved by co-expression of additional relevant pathway enzymes. Naringenin, a major Trilobatin (PubChem CID: 6451798) Naringin dihydrochalcone (PubChem CID: by-product of the initial pathway, was practically eliminated by using a chalcone synthase from barley with 9894584) unexpected substrate specificity. -
BIOLOGICAL PROPERTIES of SELECTED FLAVONOIDS of ROOIBOS (Aspalathus Linearis)
BIOLOGICAL PROPERTIES OF SELECTED FLAVONOIDS OF ROOIBOS (Aspalathus linearis) Petra W Snijman Thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Chemistry at the University of the Western Cape Study Leader: Prof IR Green Co-study Leaders: Prof E Joubert Prof WCA Gelderblom June 2007 ii DECLARATION I, the undersigned, hereby declare that the work contained in this thesis is my own original work and that I have not previously in its entirety or in part submitted it at any university for a degree. _______________________________ ____________ Petra Wilhelmina Snijman Date Copyright © 2007 University of the Western Cape All rights reserved iii ABSTRACT Bioactivity-guided fractionation was used to identify the most potent antioxidant and antimutagenic fractions contained in the methanol extract of unfermented rooibos (Aspalathus linearis), as well as the bioactive principles for the most potent antioxidant fractions. The different extracts and fractions were screened using Salmonella typhimurium tester strain TA98 and metabolically activated 2- acetoaminofluorene (2-AAF) to evaluate antimutagenic potential, while the antioxidant potency was assessed by two different in vitro assays, i.e. the inhibition of Fe(II) induced microsomal lipid peroxidation and the scavenging of the 2,2'- azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical cation. The most polar XAD fraction displayed the most protection against 2-AAF induced mutagenesis in TA98. Successive fractionation of the two XAD fractions -
Metabolic Engineering of Saccharomyces Cerevisiae for De Novo Production of Dihydrochalcones with Known Antioxidant, Antidiabetic, and Sweet Tasting Properties
Roskilde University Metabolic engineering of Saccharomyces cerevisiae for de novo production of dihydrochalcones with known antioxidant, antidiabetic, and sweet tasting properties Eichenberger, Michael; Lehka, Beata Joanna; Folly, Christophe; Fischer, David; Martens, Stefan; Simon, Ernesto; Naesby, Michael Published in: Metabolic Engineering DOI: 10.1016/j.ymben.2016.10.019 Publication date: 2017 Document Version Publisher's PDF, also known as Version of record Citation for published version (APA): Eichenberger, M., Lehka, B. J., Folly, C., Fischer, D., Martens, S., Simon, E., & Naesby, M. (2017). Metabolic engineering of Saccharomyces cerevisiae for de novo production of dihydrochalcones with known antioxidant, antidiabetic, and sweet tasting properties. Metabolic Engineering, 39, 80-89. https://doi.org/10.1016/j.ymben.2016.10.019 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact [email protected] providing -
WO 2017/117099 Al 6 July 2017 (06.07.2017) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/117099 Al 6 July 2017 (06.07.2017) P O P C T (51) International Patent Classification: (US). GENESKY, Geoffery [FR/FR]; 14 Rue Royale, Λ 61Κ 8/04 (2006.01) A61K 8/97 (201 7.01) 75008 Paris (FR). A61K 8/06 (2006.01) A61K 31/70 (2006.01) (74) Agent: BALLS, R., James; Polsinelli PC, 1401 Eye A61K 8/34 (2006.01) A61K 31/351 (2006.01) Street, N.W., Suite 800, Washington, DC 20005 (US). A61K 8/60 (2006.01) A61K 31/355 (2006.01) A61K 5/67 (2006.01) A61K 31/7048 (2006.01) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, PCT/US20 16/068662 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 27 December 2016 (27. 12.2016) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (25) Filing Language: English MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (26) Publication Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (30) Priority Data: TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 62/272,326 29 December 201 5 (29. -
Hemisynthesis and Biological Evaluation of Cinnamylated, Benzylated, and Prenylated Dihydrochalcones from a Common Bio-Sourced Precursor
antibiotics Article Hemisynthesis and Biological Evaluation of Cinnamylated, Benzylated, and Prenylated Dihydrochalcones from a Common Bio-Sourced Precursor Anne Ardaillou, Jérôme Alsarraf * , Jean Legault, François Simard and André Pichette * Centre de Recherche sur la Boréalie (CREB), Laboratoire d’Analyse et de Séparation des Essences Végétales (LASEVE), Université du Québec à Chicoutimi, 555 Boulevard de l’Université, Chicoutimi, QC G7H 2B1, Canada; [email protected] (A.A.); [email protected] (J.L.); [email protected] (F.S.) * Correspondence: [email protected] (J.A.); [email protected] (A.P.); Tel.: +1-418-545-5011 (ext. 2273) (J.A.); +1-418-545-5011 (ext. 5081) (A.P.) Abstract: Several families of naturally occurring C-alkylated dihydrochalcones display a broad range of biological activities, including antimicrobial and cytotoxic properties, depending on their alkylation sidechain. The catalytic Friedel–Crafts alkylation of the readily available aglycon moiety of neohesperidin dihydrochalcone was performed using cinnamyl, benzyl, and isoprenyl alcohols. This procedure provided a straightforward access to a series of derivatives that were structurally related to natural balsacones, uvaretin, and erioschalcones, respectively. The antibacterial and cytotoxic potential of these novel analogs was evaluated in vitro and highlighted some relations between the structure and the pharmacological properties of alkylated dihydrochalcones. Citation: Ardaillou, A.; Alsarraf, J.; Legault, J.; Simard, F.; Pichette, A. Keywords: antibacterial; Brønsted acid catalysis; dihydrochalcone; Friedel–Crafts alkylation; hemisyn- Hemisynthesis and Biological thesis; natural products; Staphylococcus aureus Evaluation of Cinnamylated, Benzylated, and Prenylated Dihydrochalcones from a Common Bio-Sourced Precursor. Antibiotics 1. Introduction 2021, 10, 620. https://doi.org/ Dihydrochalcones (DHCs) are a class of natural phenylpropanoids derived from 10.3390/antibiotics10060620 the biosynthetic pathway of shikimic acid [1]. -
Glucosyl Dihydrochalcones As Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation † ‡ † † † ‡ Ana R
Article pubs.acs.org/jmc Targeting Type 2 Diabetes with C‑Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation † ‡ † † † ‡ Ana R. Jesus, , Diogo Vila-Vicosa,̧ Miguel Machuqueiro, Ana P. Marques, Timothy M. Dore,*, † and Ameliá P. Rauter*, † Centro de Química e Bioquímica, Faculdade de Ciencias,̂ Universidade de Lisboa, Ed C8, Piso 5, Campo Grande, 1749-016 Lisboa, Portugal ‡ New York University Abu Dhabi, P.O. Box 129188, Abu Dhabi, United Arab Emirates *S Supporting Information ABSTRACT: Inhibiting glucose reabsorption by sodium glucose co-transporter proteins (SGLTs) in the kidneys is a relatively new strategy for treating type 2 diabetes. Selective inhibition of SGLT2 over SGLT1 is critical for minimizing adverse side effects associated with SGLT1 inhibition. A library of C-glucosyl dihydrochalcones and their dihydrochalcone and chalcone precursors was synthesized and tested as SGLT1/ SGLT2 inhibitors using a cell-based fluorescence assay of glucose uptake. The most potent inhibitors of SGLT2 (IC50 = 9−23 nM) were considerably weaker inhibitors of SGLT1 − μ ff (IC50 =10 19 M). They showed no e ect on the sodium independent GLUT family of glucose transporters, and the most potent ones were not acutely toxic to cultured cells. The interaction of a C-glucosyl dihydrochalcone with a POPC membrane was modeled computationally, providing evidence that it is not a pan-assay interference compound. These results point toward the discovery of structures that are potent and highly selective inhibitors of SGLT2. ■ INTRODUCTION severe side effects in the gastrointestinal tract because it inhibits Type 2 diabetes is a chronic metabolic disease in which both SGLT1 and SGLT2, and its metabolite, phloretin, inhibits hyperglycemia results mainly from the malfunction of insulin the glucose transporter GLUT1. -
Dihydrochalcones: Methods of Acquisition and Pharmacological Properties—A First Systematic Review
molecules Review Dihydrochalcones: Methods of Acquisition and Pharmacological Properties—A First Systematic Review Monika Stompor 1,* , Daniel Broda 2 and Agata Bajek-Bil 3 1 Institute of Medical Sciences, University of Rzeszów, 35-959 Rzeszów, Poland 2 Department of Biotechnology, Institute of Biology and Biotechnology, University of Rzeszów, 35-959 Rzeszów, Poland; [email protected] 3 Faculty of Chemistry, Rzeszow University of Technology, 35-959 Rzeszów, Poland; [email protected] * Correspondence: [email protected] Academic Editor: Paola Vitale Received: 9 October 2019; Accepted: 3 December 2019; Published: 5 December 2019 Abstract: Dihydrochalcones are a class of secondary metabolites, for which demand in biological and pharmacological applications is still growing. They posses several health-endorsing properties and, therefore, are promising candidates for further research and development. However, low content of dihydrochalcones in plants along with their low solubility and bioavailability restrict the development of these compounds as clinical therapeutics. Therefore, chemomicrobial and enzymatic modifications are required to expand their application. This review aims at analyzing and summarizing the methods of obtaining dihydrochalcones and of presenting their pharmacological actions that have been described in the literature to support potential future development of this group of compounds as novel therapeutic drugs. We have also performed an evaluation of the available literature on beneficial effects of dihydrochalcones -
Metabolic Engineering of Saccharomyces Cerevisiae for De Novo Production MARK of Dihydrochalcones with Known Antioxidant, Antidiabetic, and Sweet Tasting Properties
Metabolic Engineering 39 (2017) 80–89 Contents lists available at ScienceDirect Metabolic Engineering journal homepage: www.elsevier.com/locate/ymben Original Research Article Metabolic engineering of Saccharomyces cerevisiae for de novo production MARK of dihydrochalcones with known antioxidant, antidiabetic, and sweet tasting properties Michael Eichenbergera,b, Beata Joanna Lehkac,d, Christophe Follya, David Fischera, ⁎ Stefan Martense, Ernesto Simóna, Michael Naesbya, a Evolva SA, Duggingerstrasse 23, 4153 Reinach, Switzerland b Department of Biology, Technical University Darmstadt, Schnittspahnstrasse 10, 64287 Darmstadt, Germany c Evolva Biotech A/S, Lersø Parkallé 42, 2100 Copenhagen, Denmark d Department of Science and Environment, Roskilde University, Universitetsvej 1, 4000 Roskilde, Denmark e Department of Food Quality and Nutrition, Fondazione Edmund Mach, Centro Ricerca e Innovazione, Via E. Mach 1, 38010 San Michele all’Adige (TN), Italy ARTICLE INFO ABSTRACT Chemical compounds studied in this article: Dihydrochalcones are plant secondary metabolites comprising molecules of significant commercial interest as Phloretin (PubChem CID: 4788) antioxidants, antidiabetics, or sweeteners. To date, their heterologous biosynthesis in microorganisms has been Naringenin (PubChem CID: 932) achieved only by precursor feeding or as minor by-products in strains engineered for flavonoid production. Pinocembrin (PubChem CID: 68071) Here, the native ScTSC13 was overexpressed in Saccharomyces cerevisiae to increase its side activity in Phlorizin (PubChem CID: 6072) reducing p-coumaroyl-CoA to p-dihydrocoumaroyl-CoA. De novo production of phloretin, the first committed Nothofagin (PubChem CID: 42607691) dihydrochalcone, was achieved by co-expression of additional relevant pathway enzymes. Naringenin, a major Trilobatin (PubChem CID: 6451798) Naringin dihydrochalcone (PubChem CID: by-product of the initial pathway, was practically eliminated by using a chalcone synthase from barley with 9894584) unexpected substrate specificity.